Abstract Analysis of patient's materials like cells or nucleic acids obtained in a minimally
invasive or noninvasive manner through the sampling of blood or other body fluids serves as …

Analysis of circulating nucleic acids in bodily fluids, referred to as “liquid biopsies”, is rapidly
gaining prominence. Studies have shown that cell-free DNA (cfDNA) has great potential in …

Detecting cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in plasma or serum could
serve as a “liquid biopsy”, which would be useful for numerous diagnostic applications …

Cell-free circulating DNA (cfDNA) in plasma has gained global interest as a diagnostic
material for noninvasive prenatal testing and cancer diagnosis, or the so-called “liquid …

Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

Cell-free DNA (cfDNA) methylation profiling is considered promising and potentially reliable
for liquid biopsy to study progress of diseases and develop reliable and consistent …

Liquid biopsies and, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising and potentially transformative non-invasive diagnostic approach in oncology [1 …

Detection of cellular changes in tissue biopsies has been the basis for cancer diagnostics.
However, tissue biopsies are invasive and limited by inaccuracies due to sampling …

Measuring the methylation status of cell-free DNA (cfDNA) in plasma holds great potential
for the early, noninvasive detection of cancer. Two recent papers published in Nature …

Methylation analysis of circulating cell-free DNA (cirDNA), as a liquid biopsy, has a
significant potential to advance the detection, prognosis, and treatment of cancer, as well as …